What is the 13F Pro Quality Score for CRSP?

13F Pro ranks CRISPR Therapeutics AG (CRSP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRSP's current score at https://13fpro.ai/company/CRSP (free sign-up required for the full ranking).

Which hedge funds own the most CRSP stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CRSP include ARK Investment Management, BlackRock,, Orbis Allan Gray Ltd. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CRSP as soon as new 13F filings post.

Where does 13F Pro source CRSP data?

All CRISPR Therapeutics AG fundamentals and ownership data come directly from SEC EDGAR. CRISPR Therapeutics AG files with the SEC under CIK 1674416. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRSP in?

CRISPR Therapeutics AG (CRSP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRSP research updated on 13F Pro?

CRSP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CRISPR Therapeutics AG(CRSP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1674416 CRSP stock profile & AI dashboard →

13F Pro Quality Score

9.7/100

Rank #2,914 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

0.3/100

Profitability

1.3/100

Balance Sheet

11.3/100

Earnings Quality

19.8/100

Free Cash Flow

1.1/100

Institutional Flow

19.4/100

Revenue Scale

2.8/100

Dilution Risk

0.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CRSP Scores 10/100

exact factor attribution · 2026-09-11

CRSP's composite is driven by earnings growth, held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.3 pts

95th pct

Institutional flow

-1.5 pts

19th pct

Shareholder dilution

-2.5 pts

0th pct

Earnings quality

-3.0 pts

20th pct

Capital efficiency

-3.9 pts

11th pct

Scale

-7.1 pts

3th pct

Profitability

-7.3 pts

1th pct

Free cash flow

-7.3 pts

1th pct

Revenue growth

-9.9 pts

0th pct

Latest change (2026-08-03): 5 → 24 · ↑ Revenue growth 0→96

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in CRSP

Events flagged as statistical outliers against CRSP's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-03
CRSP quality score jumped 20 points (4→24) on a new filing
View source filing →

CRSP Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for CRISPR Therapeutics AG (CRSP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRSP at 9.7/100 on a 32-signal composite quality model, placing it at rank #2,914 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.3) and free cash flow (1.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CRISPR Therapeutics AG reports quarterly revenue of $10.2M, net income of $-91.2M, free cash flow of $-84.1M. Top institutional holders of CRSP by reported 13-F value include ARK Investment Management, BlackRock, Orbis Allan Gray Ltd, based on the most recent SEC filings. CRSP trades on the Nasdaq exchange and files with the SEC under CIK 1674416. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRSP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CRISPR Therapeutics AG directly from SEC EDGAR. CRISPR Therapeutics AG's 13F Pro composite quality score has ranged between 7 and 24 since 2026, currently 9.7 — a declining long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about CRISPR Therapeutics AG

Quirks, history, and lore behind CRSP — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · Swiss-domiciled · listed on Nasdaq · focused on developing transformative medicines for serious diseases.
2
The Numbers
Minimal product revenue for most of its history — it has operated largely on collaboration payments and milestones — though a landmark approval brought in hundreds of millions in its first commercial year.
3
The History
Founded in 2013, just months after the core technology it's built on was published in a landmark scientific paper — it was essentially incorporated alongside the hype.
4
The Secret
Its key partner is Vertex Pharmaceuticals, with whom it co-developed a therapy for sickle cell disease and beta thalassemia — two conditions with very few prior curative options.
5
The Lore
The technology it uses won its pioneers the Nobel Prize in Chemistry in 2020 — making this one of the few public companies whose entire platform is built on a Nobel-winning discovery.
6
The Giveaway
Its name is literally the technology: gene-editing scissors that cut DNA at precise locations — and yes, the ticker even spells it out.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$10.2M

Net Income

Q2 2026

$-91.2M

Free Cash Flow

Q2 2026

$-84.1M

ROIC

Q2 2026

-20.1%

D/E Ratio

Q2 2026

0.34

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-90.6% YoY

$3.5MFY 2025

FY22 $1.2MFY23 $371.2MFY24 $37.3MFY25 $3.5M

Net Income

-58.8% YoY

$-581.6MFY 2025

FY22 $-650.2MFY23 $-153.6MFY24 $-366.3MFY25 $-581.6M

Operating Income

-42.4% YoY

$-664.6MFY 2025

FY22 $-673.2MFY23 $-222.5MFY24 $-466.6MFY25 $-664.6M

EPS (Diluted)

-49.1% YoY

$-6.47FY 2025

FY22 $-8.36FY23 $-1.94FY24 $-4.34FY25 $-6.47

Total Assets

+1.0% YoY

$2.27BFY 2025

FY22 $2.24BFY23 $2.23BFY24 $2.24BFY25 $2.27B

Total Debt

$0.00FY 2025

FY22 —FY23 —FY24 —FY25 $0.00

Op. Cash Flow

-141.7% YoY

$-345.0MFY 2025

FY22 $-495.7MFY23 $-260.4MFY24 $-142.8MFY25 $-345.0M

Free Cash Flow

-139.1% YoY

$-345.9MFY 2025

FY22 $-532.9MFY23 $-269.8MFY24 $-144.7MFY25 $-345.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$3.5M -90.6%	$37.3M -89.9%	$371.2M +30885.5%	$1.2M -99.9%	$915.0M +127154.9%	$719.0K
Net Income	$-581.6M -58.8%	$-366.3M -138.4%	$-153.6M +76.4%	$-650.2M -272.2%	$377.7M +208.3%	$-348.9M
Operating Income	$-664.6M -42.4%	$-466.6M -109.7%	$-222.5M +66.9%	$-673.2M -280.2%	$373.5M +205.4%	$-354.4M
EPS (Diluted)	$-6.47 -49.1%	$-4.34 -123.7%	$-1.94 +76.8%	$-8.36 -277.9%	$4.70 +188.8%	$-5.29
Total Assets	$2.27B +1.0%	$2.24B +0.6%	$2.23B -0.6%	$2.24B -18.5%	$2.75B +50.5%	$1.83B
Total Debt	$0.00	—	—	—	—	—
Operating Cash Flow	$-345.0M -141.7%	$-142.8M +45.2%	$-260.4M +47.5%	$-495.7M -192.0%	$539.0M +326.1%	$-238.4M
Free Cash Flow	$-345.9M -139.1%	$-144.7M +46.4%	$-269.8M +49.4%	$-532.9M -216.5%	$457.3M +278.1%	$-256.7M

Get alerted when CRSP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CRISPR Therapeutics AG including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRSP

ARK Investment Management LLC
$516.0M9,460,939 sh
BlackRock, Inc.
$455.4M8,348,977 sh
Orbis Allan Gray Ltd
$297.2M5,449,161 sh
Capital World Investors
$259.0M4,749,525 sh
STATE STREET CORP
$235.7M4,321,666 sh
GSK plc
$175.7M3,220,627 sh
GEODE CAPITAL MANAGEMENT, LLC
$136.9M2,509,915 sh
T. Rowe Price Investment Management, Inc.
$112.0M2,053,017 sh
SR ONE CAPITAL MANAGEMENT, LP
$111.2M2,038,763 sh
TWO SIGMA INVESTMENTS, LP
$108.5M1,988,621 sh

Fund	Value	Shares
ARK Investment Management LLC	$516.0M	9,460,939
BlackRock, Inc.	$455.4M	8,348,977
Orbis Allan Gray Ltd	$297.2M	5,449,161
Capital World Investors	$259.0M	4,749,525
STATE STREET CORP	$235.7M	4,321,666
GSK plc	$175.7M	3,220,627
GEODE CAPITAL MANAGEMENT, LLC	$136.9M	2,509,915
T. Rowe Price Investment Management, Inc.	$112.0M	2,053,017
SR ONE CAPITAL MANAGEMENT, LP	$111.2M	2,038,763
TWO SIGMA INVESTMENTS, LP	$108.5M	1,988,621

Companies Similar to CRSP

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

GLUE

Monte Rosa Therapeutics, Inc.

AI score

Similar quality profile · 10 shared holders

NEA Management Company, LLC Versant Venture Management, LLC Virtus Investment Advisers, LLC

NRIX

Nurix Therapeutics, Inc.

AI score

Similar quality profile · 15 shared holders

ARK Investment Management LLC Capital World Investors Nikko Asset Management Americas, Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

AI score

Similar quality profile · 10 shared holders

ARK Investment Management LLC Nikko Asset Management Americas, Inc.Hennion & Walsh Asset Management, Inc.

ZYME

Zymeworks Inc.

AI score

Similar quality profile · 6 shared holders

EcoR1 Capital, LLC Susquehanna Portfolio Strategies, LLC Virtus Investment Advisers, LLC

WVE

Wave Life Sciences, Inc.

AI score

Similar quality profile · 12 shared holders

GSK plc Susquehanna Portfolio Strategies, LLC Privium Fund Management B.V.

NAMS

NewAmsterdam Pharma Co N.V.

AI score

Similar quality profile · 12 shared holders

Capital World Investors Orbis Allan Gray Ltd Capital International Investors

RXRX

RECURSION PHARMACEUTICALS, INC.

AI score

Similar quality profile · 14 shared holders

ARK Investment Management LLC Nikko Asset Management Americas, Inc.IQ EQ FUND MANAGEMENT (IRELAND) Ltd

ZBIO

Zenas BioPharma, Inc.

AI score

Similar quality profile · 6 shared holders

SR ONE CAPITAL MANAGEMENT, LP Capital International Investors NEA Management Company, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRSP on your watchlist

Track score changes the day CRISPR Therapeutics AG files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRSP a good stock to buy?

13F Pro's AI-powered analysis of CRISPR Therapeutics AG (CRSP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRSP are available on the CRSP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CRSP is classified as a mid company.

Which hedge funds own CRSP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRSP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CRISPR Therapeutics AG's investment landscape.